<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336265">
  <stage>Registered</stage>
  <submitdate>23/11/2010</submitdate>
  <approvaldate>29/11/2010</approvaldate>
  <actrnumber>ACTRN12610001044011</actrnumber>
  <trial_identification>
    <studytitle>Vitamin D deficiency in Pregnancy - A comparison of two treatments</studytitle>
    <scientifictitle>A randomised double blinded interventional trial to determine the effect of 50,000 IU vitamin D supplementation monthly or twice monthly from 20 weeks gestation.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Vitamin D deficiency in pregnancy</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Normal metabolism and endocrine development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Pregnant women in trial will be randomly allocated to recieve either 50000IU vitamin D oral tablet supplementation monthly or twice monthly from 20 weeks gestation until birth of baby.</interventions>
    <comparator>There are two arms in the study.  One arm of the study will received 50000 IU tablets twice monthly, 2 weeks apart.  The other arm of the study will receive 50000IU monthly and a placebo monthly, 2 weeks apart from 20 weeks gestation until delivery of baby.  The placebo tablet contains lactose monohydrate, acacia, calcium carbonate, castor oil, maize starch, povidone, sucrose, purified talc, hydrated silica, powdered cellulose, magnesium sterate, shellac, gelatin, beeswax white, titanium dioxide and prepared theobroma.</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Cord blood samples will be taken at delivery.  If emergencies at delivery prevent a cord blood sample being taken then a maternal venous blood sample will be taken for analysis.  The blood will be stored as per Capital and Coast laboratory protocols and will be analysed in batches to limit between test variation.</outcome>
      <timepoint>At delivery of newborn</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the vitamin D supplementation required to ensure vitamin D repletion at delivery, and by proxy for newborns to begin life with adequate vitamin D stores.  T-tests will be carried out to compare the mean improvement in serum vitamin D levels between the two different treatment doses</outcome>
      <timepoint>At delivery of newborn</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Pregnant women seeking maternity care with midwifery services involved in the study.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>If antenatal Vitamin D level is &gt; 75nmol/litre when enrolling in study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>All women seeking maternity care with Newtown Union Health and Nga Tapuhiwhakawhanau midwifery services will be invited to enrol in study and will have their vitamin D levels measured by 16 weeks gestation.  Those with vitamin D &lt;75nmol/l will be randomly and blindly allocated to receive 50,000IU monthly or twice monthly.</concealment>
    <sequence>When a woman's blood test results are received and eligible for the trial, they will be allocated in a predetermined and random manner by serially tossing of a coin.  Allocation is not concealed.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/06/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Newtown Union Health Service</primarysponsorname>
    <primarysponsoraddress>14 Hall Ave
Newtown
Wellington
6021</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Royal New Zealand College of GP's</fundingname>
      <fundingaddress>Level 3
88 The Terrace
Wellington
6011</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>Wellington Medical Research Foundation</sponsorname>
      <sponsoraddress>PO Box 51 211
Wellington
6011
New Zealand</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Jeremy Krebs</othercollaboratorname>
      <othercollaboratoraddress>Endocrinologist
Capital and Coast Health
Riddiford Street
Wellington
6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Central Ethics Committee</ethicname>
      <ethicaddress>Level 1
1 The Terrace
Wellington
6011</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>30/11/2010</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Jeremy Krebs</name>
      <address>Capital and Coast Health
Riddiford Street
Newtown
Wellington
6021</address>
      <phone>644 3855999</phone>
      <fax />
      <email>jeremy.krebs@ccdhb.org.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Annie Judkins</name>
      <address>Newtown Union Health Service
14 Hall Ave
Newtown 
Wellington
6021</address>
      <phone>644 3802020</phone>
      <fax />
      <email>annie.judkins@nuhs.org.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Annie Judkins</name>
      <address>Newtown Union Health Service
14 Hall Ave
Newtown 
Wellington
6021</address>
      <phone />
      <fax />
      <email />
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>